BD’s Onclarity HPV Assay: What it means for the future of cervical cancer detection

Pathology expert Mark H. Stoler, MD, discussed the BD Onclarity™ HPV Assay for primary HPV screening and what it means for the future of cervical cancer detection.

Becton, Dickinson and Company's (BD) Onclarity HPV Assay received FDA approval in August 2021, making it the only assay currently approved that individually identifies and reports HPV genotypes 31, 51, 52, 33/58, 35/39/68, and 56/59/66, as well as the standard 16,18, and 45.

Mark H. Stoler, MD, professor of pathology, cytology, and gynecology in the department of cytology, University of Virginia, focuses his research efforts on molecular analysis of gene expression as applied to oncologic pathology.

Disclosures: Stoler is a consultant for BD Diagnostics.

Download the ASCCP Management Guidelines app